

Publication of interim report January – March 2026

OSLO, NORWAY – May 28, 2026: Genetic Analysis AS ("GA" or the "Company") hereby publishes the interim report for the period January – March 2026. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Ronny Hermansen, CEO of Genetic Analysis, comments:

"The first quarter of 2026 was marked by continued progress for Genetic Analysis, with strong growth in recurring GA-map® kit sales and further advancement of our microbiome-based diagnostics pipeline. The development confirms the relevance of our standardized GA-map® platform and supports our strategy to build scalable revenues through partner laboratories, reagent-kit sales and new diagnostic applications."

(NOK thousand)	Q1 2026	Q1 2025	FY 2025
Sales revenue	3,849	2,403	16,712
Other income	542	1,612	4,460
Operating income	4,391	4,015	21,172
Cost of goods sold	1,032	395	4,700
Gross profit	3,359	3,620	16,472
Operating expenses (ex. depr. & amort.)	6,553	6,745	22,563
EBITDA	-3,195	-3,125	-6,091
Net profit/loss	-4,606	-4,588	-11,413
Earnings per share (NOK)	-0.07	-0.09	-0.18

(NOK thousand)	2026-03-31	2025-03-31	FY 2025
Total non-current assets	21,701	20,167	21,374
Total current assets	27,509	18,005	31,072
Total equity	22,473	17,995	27,079
Total non-current liabilities	8,722	7,863	6,401
Total current liabilities	18,015	12,314	18,966
Cash and cash equivalents (*)	20,028	10,696	24,029
Equity ratio (%)	46%	47%	52%

*Includes a positive impact from customer pre-payment.

Definitions:

- Equity ratio: Shareholder's equity as a proportion of total assets.
- Earnings per share: Profit/Loss for the period divided by an average number of shares.
- Constant currency: This year's sales converted to NOK by using last year's exchange rates.

Revenues and Gross margin

Sales revenue (excluding grants) reached NOK 3.8 million in Q1 2026, an increase of 60.2% compared to Q1 2025.

Key product sales (GA map® Reagent kits) reached NOK 3.5 million in Q1:

- Up 68.3% in Q1 2026 compared to Q1 2025. The weaker USD against NOK has negatively impacted sales, and thus the underlying reagent kit sales growth has been even stronger.

Gross margin was NOK 2.8 million in Q1 2026, corresponding to a gross margin of 73.2%, compared to NOK 2.0 million and 83.6% in Q1 2025. Gross margin% was negatively affected by the US customs duties and a weaker USD.

Cost of goods sold totaled NOK 1.0 million in Q1 2026, compared to NOK 0.4 million in Q1 2025, and included customs duties of NOK 0.3 million (0 in Q1-25).

EBITDA

EBITDA in Q1 2026 totaled NOK -3.2 million (NOK -3.1 million in Q1 2025).

Cash Flow and Liquidity

- Cash and cash equivalents: NOK 20.0 million on 31 March 2026 compared to NOK 24.0 million on 31 December 2025.

Highlights during Q1 2026

- On February 12, Genetic Analysis announced that its important patent application (CA2980637) had been allowed for grant in Canada. The patent covers the Company's unique algorithm for profiling gut microbiota incorporated in the GA-map® technology.
- On February 19, Genetic Analysis announced that its patent application US2017/0369941 had been allowed for grant by the United States Patent and Trademark Office (USPTO). The patent strengthens the protection of GA's proprietary diagnostic technology.
- On March 12, Genetic Analysis announced the launch of GA-map® Dysbiosis Test AInsight, an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of microbiome testing in clinical practice.

Highlights after the end of the period

- On April 30, Genetic Analysis announced its attendance at Digestive Disease Week (DDW) congress in Chicago, May 3 - 5 2026. The company used the meeting to launch AInsight and highlight its upcoming product, GA-map® IBD Precision Dx, a next-generation diagnostic solution for personalized management in inflammatory bowel disease (IBD).

Press release

28-05-2026



- On May 7, Genetic Analysis announced that the USPTO granted a U.S. patent no. 12,596,121 covering a diagnostic method to assess the likelihood that IBS patients will respond to treatment with a low-FODMAP diet or Faecal Microbiota Transplant (FMT).

For further information, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

This disclosure contains information that Genetic Analysis AS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, at the time indicated by Genetic Analysis AS news distributor upon publication of this press release.

About Genetic Analysis:

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA's vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.

For more general information: www.genetic-analysis.com

Interested in reading more about GA's products? Please visit www.ga-map.com

Stay updated on GA and sign up for more investor-related information:

<https://www.geneticanalysis.com/subscriptions/>